Opposing effects of acute versus chronic inhibition of p53 on decitabine’s efficacy in myeloid neoplasms

Decitabine is a DNA methyltransferase inhibitor and is considered a promising drug to treat myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) with p53 mutations. However, whether loss of p53 in fact increases the response of MDS/AML cells to decitabine remains unclear. In this study,...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Sci Rep
Autors principals: Tamura, Moe, Yonezawa, Taishi, Liu, Xiaoxiao, Asada, Shuhei, Hayashi, Yasutaka, Fukuyama, Tomofusa, Tanaka, Yosuke, Kitamura, Toshio, Goyama, Susumu
Format: Artigo
Idioma:Inglês
Publicat: Nature Publishing Group UK 2019
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6547685/
https://ncbi.nlm.nih.gov/pubmed/31160638
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41598-019-44496-6
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars